Browsing by author "Somaiah, Navita"
Now showing items 21-37 of 37
-
Influence of Confounding Factors on Radiation Dose Estimation Using In Vivo Validated Transcriptional Biomarkers.
Cruz-Garcia, L; O'Brien, G; Donovan, E; Gothard, L; Boyle, S; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2018-07-01)For triage purposes following a nuclear accident, blood-based gene expression biomarkers can provide rapid dose estimates for a large number of individuals. Ionizing-radiation-responsive genes are regulated through the DNA ... -
Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial.
Nimalasena, S; Gothard, L; Anbalagan, S; Allen, S; Sinnett, V; et al. (ELSEVIER SCIENCE INC, 2020-11-15)PURPOSE: Hydrogen peroxide (H2O2) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment ... -
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; et al. (ELSEVIER SCIENCE INC, 2018-06-01)PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ... -
Local control and toxicity after hypofractionated accelerated palliative RT in breast cancer
Webb, K; Gothard, L; Mohammed, K; Kirby, A; Locke, I; et al. (ELSEVIER IRELAND LTD, 2022-05-01) -
Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer.
Webb, K; Gothard, L; Mohammed, K; Kirby, AM; Locke, I; et al. (ELSEVIER SCIENCE LONDON, 2023-09-01)AIMS: For patients with locally advanced primary/recurrent breast cancer, radiotherapy is an effective treatment for locoregional control. 36 Gy in 6 Gy once-weekly fractions is a commonly used schedule, but there are no ... -
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins, A; Gusterson, B; Tovey, H; Griffin, C; Stuttle, C; et al. (ELSEVIER, 2023-02-01)BACKGROUND: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A ... -
Outcomes of Different Quality of Life Assessment Modalities After Breast Cancer Therapy: A Network Meta-analysis.
Kastora, SL; Holmquist, A; Valachis, A; Rocco, N; Meattini, I; et al. (AMER MEDICAL ASSOC, 2023-06-01)IMPORTANCE: Improvement in clinical understanding of the priorities of patients with breast cancer (BC) regarding postoperative aesthetic outcomes (AOs) is needed. OBJECTIVE: To assess expert panel and computerized evaluation ... -
PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance.
Feng, H; Lane, KA; Roumeliotis, TI; Jeggo, PA; Somaiah, N; et al. (COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2022-07-28)The PBRM1 subunit of the PBAF (SWI/SNF) chromatin remodeling complex is mutated in ∼40% of clear cell renal cancers. PBRM1 loss has been implicated in responses to immunotherapy in renal cancer, but the mechanism is unclear. ... -
Preoperative breast radiation therapy: Indications and perspectives.
Lightowlers, SV; Boersma, LJ; Fourquet, A; Kirova, YM; Offersen, BV; et al. (ELSEVIER SCI LTD, 2017-09-01)Preoperative breast radiation therapy (RT) is not a new concept, but older studies failed to change practice. More recently, there has been interest in revisiting preoperative RT using modern techniques. This current ... -
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study.
Thiruchelvam, PTR; Leff, DR; Godden, AR; Cleator, S; Wood, SH; et al. (ELSEVIER SCIENCE INC, 2022-04-07)BACKGROUND: Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. However, evidence for this treatment ... -
Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy.
Wedlake, L; Shaw, C; McNair, H; Lalji, A; Mohammed, K; et al. (OXFORD UNIV PRESS, 2017-09-01)Background: Therapeutic radiotherapy is an important treatment of pelvic cancers. Historically, low-fiber diets have been recommended despite a lack of evidence and potentially beneficial mechanisms of fiber.Objective: ... -
Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.
Wilkins, A; Melcher, A; Somaiah, N (ELSEVIER SCIENCE LONDON, 2018-10-01) -
Science in Focus; Biological optimisation of radiotherapy fraction
Somaiah, N; Wilkins, A; Melcher, A -
The applicability of scoring calyculin A-induced premature chromosome condensation (PCC) objects for dose assessment including for radiotherapy patients.
Sun, M; Moquet, J; Lloyd, D; Barnard, S; Anbalagan, S; et al. (S. Karger AG, 2023-10-19)As an extension to a previous study, a linear calibration curve covering doses from 0 to 10 Gy was constructed and evaluated in the present study using calyculin A-induced premature chromosome condensation (PCC) by scoring ... -
The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Workshop: Translating Novel Discoveries to and from the Clinic.
Chan Wah Hak, C; Dean, JA; Hill, MA; Somaiah, N; National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group 1(☆), (ELSEVIER SCIENCE LONDON, 2023-12-01) -
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.
Anbalagan, S; Ström, C; Downs, JA; Jeggo, PA; McBay, D; et al. (NATURE PORTFOLIO, 2021-03-29)Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient ...